Navigation Links
AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
Date:2/23/2009

LONDON, Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated when compared with placebo.

AstraZeneca (NYSE: AZN) will work with MAP Pharmaceuticals to conduct further analyses of these data to determine appropriate next steps for the program.

AstraZeneca and MAP Pharmaceuticals have a collaboration agreement to develop and commercialize UDB.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
5. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
6. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
7. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
10. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
11. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... NEW YORK , Feb. 10, 2016 ... clinical-stage biopharmaceutical company, announced today that it has filed ... Myeloid Leukemia and other cancers. --> ... of treating cancer by administration of Ceplene (histamine dihydrochloride) ... also provides methods of predicting the efficacy of Ceplene ...
(Date:2/10/2016)... , Feb. 10, 2016  Oxis International Inc. ... drug, OXS-1550, was described as a "clinical trial triumph" ... drug went into complete cancer remission. ... of Minnesota Masonic Cancer Center. --> ... of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... Massachusetts (PRWEB) , ... February 10, 2016 , ... ... models to effectively measure change in their patients. Research shows that the Goal ... methods. To help therapists overcome this challenge and learn more about the Goal ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... has been awarded the prestigious Distinguished Emerald Club of the World award, as ... BoardRoom magazine, one of the most respected trade publications serving private clubs. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... FL 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm – ... – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: ...
(Date:2/10/2016)... ... February 10, 2016 , ... The recreational use of marijuana has ... state still face a lot of restrictions as to where they can smoke pot. ... personal use” and that cannabis “may not be consumed openly or publicly.” , Given ...
(Date:2/10/2016)... Puente, California (PRWEB) , ... February 09, 2016 ... ... Medicine students, faculty and staff helped give free oral screenings to 150 children ... Feb. 5, 2016. , The College of Dental Medicine joined Chinese American Dental ...
Breaking Medicine News(10 mins):